Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidance On Lab-Developed Tests, Adverse Event Reporting Among US FDA's Priorities For FY 2016

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration's device center has released its annual guidance priority list1, saying it "fully intends" to release final guidance documents on the Medical Device Reporting regulation, Unique Device Identification direct marking, regulatory oversight of laboratory-developed tests and use of ISO 10993-1 biocompatibility standards, among others1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

MT040685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel